Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: June 28, 2012
Last updated: September 7, 2017
Last verified: September 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 1, 2020|
|Primary Completion Date:||October 10, 2013 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||March 13, 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, Griffith SK, St Clair MH, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015 Oct;15(10):1145-55. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19.